Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial
- Resource Type
- Article
- Source
- In
European Journal of Cancer December 2022 177:63-71 - Subject
- Language
- ISSN
- 0959-8049